{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:13:10Z","timestamp":1785172390289,"version":"3.55.0"},"reference-count":14,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sci.","Brain Sciences"],"abstract":"<jats:p>Background\/Objectives: Cannabis use is prevalent in first-episode psychosis (FEP) and is associated with poor clinical outcomes. Cariprazine, a dopamine D3\/D2 partial agonist with preferential D3 affinity, may offer clinical advantages for both psychotic symptoms and comorbid substance use; however, naturalistic data in FEP patients with active cannabis use are lacking. Methods: We conducted a retrospective naturalistic case series of eight FEP patients with active cannabis use treated with cariprazine for six months across two Greek Early Intervention Units (PNOES Athens and Thessaloniki, EPAPSY). Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) Five-Factor (Marder) model and cannabis use using the Cannabis Experience Questionnaire (CEQ) at baseline and six months. Analyses were descriptive, with exploratory Wilcoxon signed-rank tests. Results: At six months, lower mean PANSS scores were observed for positive symptoms (12.88 vs. 9.50), disorganization (11.38 vs. 9.13) and, to a lesser degree, anxiety\/depression (9.38 vs. 8.50). Negative symptoms changed little (16.13 vs. 15.00), and hostility was essentially unchanged (10.63 vs. 11.63). Only the reduction in positive symptoms reached nominal significance (p = 0.047; dz = \u22121.05), which did not survive correction for multiple comparisons. Cannabis-use frequency decreased in seven of eight participants, with two reporting complete cessation. Conclusions: These preliminary, hypothesis-generating observations suggest that cariprazine may warrant further study in FEP with comorbid cannabis use. The findings cannot be interpreted as evidence of efficacy given the small, uncontrolled, diagnostically heterogeneous sample.<\/jats:p>","DOI":"10.3390\/brainsci16080787","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:11:56Z","timestamp":1785168716000},"page":"787","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cariprazine in First-Episode Psychosis with Comorbid Cannabis Use: A Case Series of Eight Patients from Two Greek Early Intervention Units"],"prefix":"10.3390","volume":"16","author":[{"given":"Evangelos","family":"Ntouros","sequence":"first","affiliation":[{"name":"Association for Regional Development and Mental Health (EPAPSY), 15124 Athens, Greece"},{"name":"2nd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, 56430 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina-Christina","family":"Partsanaki","sequence":"additional","affiliation":[{"name":"Association for Regional Development and Mental Health (EPAPSY), 15124 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-1487","authenticated-orcid":false,"given":"Stefanos","family":"Dimitrakopoulos","sequence":"additional","affiliation":[{"name":"Association for Regional Development and Mental Health (EPAPSY), 15124 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Ioanna","family":"Nazlidou","sequence":"additional","affiliation":[{"name":"Association for Regional Development and Mental Health (EPAPSY), 15124 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilis-Ilias","family":"Spatharas","sequence":"additional","affiliation":[{"name":"Association for Regional Development and Mental Health (EPAPSY), 15124 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venetsanos","family":"Mavreas","sequence":"additional","affiliation":[{"name":"Association for Regional Development and Mental Health (EPAPSY), 15124 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-0807","authenticated-orcid":false,"given":"Vasilis P.","family":"Bozikas","sequence":"additional","affiliation":[{"name":"2nd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, 56430 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/NMD.0000000000000284","article-title":"Early Intervention in Psychosis: Obvious, Effective, Overdue","volume":"203","author":"McGorry","year":"2015","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/schbul\/sbv016","article-title":"A Systematic Review of the Effect of Early Interventions for Psychosis on the Usage of Inpatient Services","volume":"41","author":"Randall","year":"2015","journal-title":"Schizophr. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/0004867415599846","article-title":"Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use","volume":"50","author":"Myles","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Seti\u00e9n-Suero, E., Neergaard, K., Ram\u00edrez-Bonilla, M., Correa-Ghisays, P., Fa\u00f1an\u00e1s, L., Crespo-Facorro, B., and Ayesa-Arriola, R. (2017). Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183613"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S0033291713000433","article-title":"Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: A 5-year follow-up study of patients in the OPUS trial","volume":"44","author":"Clausen","year":"2014","journal-title":"Psychol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1080\/14656566.2023.2266359","article-title":"The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder","volume":"24","author":"Grunze","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Barabassy, A., Csehi, R., Dombi, Z.B., Szatm\u00e1ri, B., Brevig, T., and N\u00e9meth, G. (2025). Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals, 18.","DOI":"10.3390\/ph18070995"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/YIC.0000000000000568","article-title":"Cariprazine as a maintenance treatment in dual schizophrenia: A 6-month observational study in patients with schizophrenia and cannabis use disorder","volume":"40","author":"Szerman","year":"2025","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/acps.13081","article-title":"Stopping cannabis use benefits outcome in psychosis: Findings from 10-year follow-up study in the PAFIP-cohort","volume":"140","author":"Neergaard","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_10","first-page":"317","article-title":"Tobacco and Alcohol and Cannabis Experience Questionnaires. Greek translation and test-retest reliability","volume":"33","author":"Kollias","year":"2022","journal-title":"Psychiatriki"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Taube, M. (2021). Case Report: Severe Side Effects Following Treatment With First Generation Antipsychotics While Cariprazine Leads to Full Recovery. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.804073"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Coentre, R., Saraiva, R., Sereijo, C., and Levy, P. (2021). Cariprazine Use in Early Psychosis: Three Case Reports. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.788281"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1192\/bjo.2022.56","article-title":"Cariprazine as a treatment for negative psychotic symptoms in first-episode psychosis: Case series","volume":"8","author":"Demjaha","year":"2022","journal-title":"BJPsych Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2009.04.005","article-title":"Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study)","volume":"113","author":"Baeza","year":"2009","journal-title":"Schizophr. Res."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/8\/787\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:26:32Z","timestamp":1785169592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/8\/787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,26]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["brainsci16080787"],"URL":"https:\/\/doi.org\/10.3390\/brainsci16080787","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,26]]}}}